Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
01:15am, Tuesday, 25'th Nov 2025
Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition an
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The only gene replacement therapy for children two years and older, teens, and
FDA approves Novartis' gene therapy for rare muscle disorder
05:26pm, Monday, 24'th Nov 2025
U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III s
Bahl & Gaynor Inc. Trims Stock Holdings in Novartis AG $NVS
04:07am, Sunday, 23'rd Nov 2025
Bahl and Gaynor Inc. lowered its holdings in shares of Novartis AG (NYSE: NVS) by 2.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
Novartis AG (NVS) Shareholder/Analyst Call Transcript
05:53pm, Friday, 21'st Nov 2025
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
11:15am, Friday, 21'st Nov 2025
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Novartis AG (NVS) Shareholder/Analyst Call Transcript
05:13pm, Thursday, 20'th Nov 2025
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 3:00 AM EST Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
12:43pm, Thursday, 20'th Nov 2025
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into
Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower
10:49am, Thursday, 20'th Nov 2025
Novartis (NVS) just turned up the volume on its cancer ambitions, raising the ceiling on two of its most important oncology bets in a move that could reshape ho
Novartis Expects Steady Sales Growth Through 2030
01:51am, Thursday, 20'th Nov 2025
The pharma giant said it is well positioned beyond the decade, citing higher expectations for key drugs.
Novartis targets 5%-6% annual sales growth until 2030 on key drugs
01:09am, Thursday, 20'th Nov 2025
Switzerland's Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030 for the group, underpinned by higher peak revenue expectations for its drugs Kisqali and Scemblix.
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
01:00am, Thursday, 20'th Nov 2025
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for K
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
01:51pm, Wednesday, 19'th Nov 2025
Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmac
Novartis announces plans to build flagship manufacturing hub in North Carolina
12:30pm, Wednesday, 19'th Nov 2025
East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub
